Pet Diabetes Care Devices Market By Product Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices); By Animal Type (Dogs, Cats); By End User (Veterinary Hospitals & Clinics, Home Care); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Pet Diabetes Care Devices Market is poised to expand steadily at a projected CAGR of 7.5%, standing at USD 1.8 billion in 2024 and expected to reach USD 2.8 billion by 2030, according to internal estimates by Strategic Market Research.

 

Pet diabetes — mainly Type 1 — is becoming more common as pets live longer and owners become more aware of chronic conditions. This market centers on devices that help monitor and manage glucose levels in dogs and cats, including blood glucose meters, continuous glucose monitoring (CGM) tools, and insulin delivery systems adapted for veterinary use.

 

Rising pet ownership, greater spending on companion animal health, and stronger vet infrastructure in developed regions are driving this market. At the same time, more companies are investing in easy-to-use devices that pet owners can manage at home — a big shift that reduces clinic visits but demands accurate, user-friendly technology.

 

Key stakeholders include device manufacturers, veterinary hospitals, animal clinics, pet insurers, and pharmacies. Governments and wellness-focused organizations are also shaping market expansion, while investors increasingly target remote glucose monitoring startups as the next growth catalyst.

 

Ultimately, this market reflects the growing humanization of pets — owners seeking the same high-quality, connected care for animals that they expect for themselves.

 

Market Segmentation And Forecast Scope

The Pet Diabetes Care Devices Market divides across Product Type, Animal Type, End User, and Region.

By Product Type

The market splits into Blood Glucose Monitoring Devices and Insulin Delivery Devices. Monitoring tools — glucose meters, test strips, and CGMs — hold around 65% market share in 2024, as frequent glucose checks remain essential. Insulin delivery devices — pens, syringes, and pumps — are gaining traction with at-home use on the rise.

 

By Animal Type

Dogs lead the market due to higher diabetes prevalence and earlier diagnosis rates. Cats follow, while niche interest exists for smaller pets such as ferrets, though volumes remain minimal.

 

By End User

The primary end users are Veterinary Hospitals & Clinics and Home Care Settings. Clinics dominate for diagnosis and initial treatment, but the home-care segment is expanding rapidly as owners seek convenience and cost savings. Continuous glucose monitors are expected to outpace traditional glucose meters in growth over time.

 

By Region

North America dominates the global market with high pet healthcare spending and advanced vet networks. Europe follows closely with strong pet insurance coverage. Asia Pacific is emerging as the fastest-growing region, led by urban China, Japan, and South Korea. Latin America and Middle East & Africa are slower but show rising adoption in premium clinics.

 

Market Trends And Innovation Landscape

Innovation in the Pet Diabetes Care Devices Market is advancing rapidly, primarily driven by technology transfer from human diabetes management to veterinary applications. The most transformative trend is the rise of Continuous Glucose Monitoring (CGM) systems designed specifically for animals. Once exclusive to human healthcare, CGMs are now being adapted with smaller, softer sensors and pet-friendly adhesives to enable continuous, accurate glucose tracking with minimal discomfort.

 

A growing number of startups and established animal health firms are exploring smart wearables — including collars and harnesses with built-in sensors that connect to mobile applications. These solutions allow pet owners and veterinarians to receive real-time alerts when glucose levels rise or fall outside the safe range, helping prevent emergencies and improving quality of life for diabetic pets.

 

Another key development is digital integration and remote monitoring. Devices are no longer stand-alone meters; they are becoming part of connected care ecosystems that sync with veterinary dashboards, mobile apps, and cloud-based platforms. This data connectivity enables veterinarians to monitor patients remotely, adjust insulin dosage based on daily readings, and provide teleconsultations — a convenience highly valued by busy pet owners.

 

On the insulin delivery side, R&D is focusing on minimally invasive and long-acting delivery methods. Some firms are piloting implantable micro-pumps and insulin patches designed for small animals, aiming to replace daily injections. While these products are still in the early testing phase, they signal a shift toward improved compliance and comfort for both pets and owners.

 

The regulatory environment is evolving as well. Authorities in North America and Europe are tightening approval requirements for veterinary-grade medical devices, prompting manufacturers to invest more in safety validation and real-world data collection. However, this is also boosting confidence among veterinarians and pet owners regarding product reliability.

 

Strategic collaborations are another defining trend. Partnerships between pet tech startups and large veterinary pharmaceutical companies are accelerating commercialization and global reach. Human diabetes device manufacturers are also leveraging existing intellectual property to develop pet-specific models, significantly shortening time to market.

 

In short, the market’s innovation trajectory centers on smart connectivity, comfort-driven design, and data-enabled precision — making diabetes management for pets simpler, safer, and more consistent.

 

Competitive Intelligence And Benchmarking

The competitive landscape of the pet diabetes care devices market includes a blend of major animal health corporations, specialized veterinary device firms, and human diabetes technology companies expanding into the pet sector. The race for leadership revolves around device accuracy, user experience, and digital integration rather than just pricing.

 

Zoetis remains the global leader, leveraging its strong veterinary partnerships and broad product portfolio. The company invests heavily in professional training for clinics, ensuring consistent use of its glucose monitoring systems and fostering long-term loyalty.

Merck Animal Health focuses on accessible glucose monitoring kits and insulin solutions bundled as treatment packages. Their strategy combines reliability and affordability, making them a preferred brand among general veterinary practices.

Boehringer Ingelheim Animal Health maintains a competitive edge through licensing collaborations with human diabetes tech innovators, enabling rapid adaptation of CGM platforms for veterinary applications. This approach allows faster regulatory submission and a broader geographic rollout.

Elanco is building its presence through pilot collaborations with veterinary hospital networks, using clinical feedback to refine new digital glucose meters and app-based insulin tracking tools.

UltiMed and PetTest are gaining traction in the direct-to-consumer segment. Their glucose meters and testing kits are known for simplicity and affordability, appealing to first-time pet owners and smaller veterinary clinics. PetTest’s latest Bluetooth-enabled glucose monitor exemplifies the trend toward home-based care.

Trividia Health, with its strong background in human diabetes care, has efficiently repurposed its proven glucose monitoring technology for pets, minimizing R&D costs and positioning itself as a mid-tier price leader.

 

A noteworthy emerging strategy involves pet insurance integrations. Some manufacturers are collaborating with insurers to bundle diabetes device costs into health plans, reducing the financial burden for owners and improving adoption rates — particularly across Europe and North America.

 

Ultimately, success in this market hinges on building trust among veterinarians, offering owner-friendly devices, and maintaining robust after-sales support rather than aggressive price competition.

 

Regional Landscape And Adoption Outlook

Geographical dynamics strongly influence adoption patterns within the pet diabetes care devices market. North America holds the largest market share, led by the United States. High pet healthcare expenditure, advanced veterinary infrastructure, and widespread insurance coverage underpin strong device uptake. Most pet owners are already familiar with glucose meters and digital monitoring tools, ensuring quick adoption of next-generation CGMs.

 

Canada follows similar trends, with growing awareness and increased spending on chronic pet disease management. The integration of mobile health platforms into clinic operations is boosting continuous monitoring adoption.

 

Europe is the second-largest market, led by the United Kingdom, Germany, and the Nordic countries. Strong pet insurance penetration supports steady sales of glucose meters and insulin devices. Western Europe is mature, but Eastern Europe is now accelerating as urbanization and middle-class pet ownership rise.

 

Asia Pacific represents the fastest-growing region. Japan and South Korea show high adoption rates due to well-established vet care networks, while China and India are seeing a surge in pet ownership, creating a large, underserved market for affordable devices. Manufacturers are investing in localized production and education programs to expand reach in these regions.

 

Latin America and the Middle East & Africa currently contribute modest shares, with demand concentrated in urban centers like São Paulo, Dubai, and Cape Town. Wealthier households and premium clinics in these cities are early adopters of advanced diabetes monitoring tools.

 

Across all regions, a major opportunity lies in telehealth and mobile veterinary services. These platforms are extending access to glucose monitoring devices in rural or semi-urban areas where clinic infrastructure remains limited.

 

Overall, North America dominates in scale, Europe ensures stability through policy support, and Asia Pacific leads in growth — defining the market’s global equilibrium heading toward 2030.

 

End-User Dynamics And Use Case

The end-user landscape of the Pet Diabetes Care Devices Market is evolving as responsibility for diabetes management gradually shifts from clinics to owners’ homes. Currently, veterinary hospitals and clinics account for most device usage and purchases. They handle diagnosis, initial training, and ongoing monitoring. Vets also play a critical role in product selection — their brand recommendations significantly influence owner purchasing behavior.

 

However, the most dynamic growth is occurring within the home care segment. Pet owners increasingly seek autonomy in managing daily glucose monitoring and insulin delivery. This transition is fueled by portable, app-enabled glucose meters and wearable CGMs that transmit readings directly to veterinarians via cloud dashboards. The convenience of home testing reduces repeat clinic visits while maintaining professional oversight.

 

Many veterinary clinics are adapting to this shift by offering short training workshops or tele-guidance programs to ensure safe and accurate home usage. Pharmacies and e-commerce platforms are emerging as important secondary distribution channels, bundling supplies such as test strips and syringes through subscription models.

 

Use Case Example: A pet owner in Toronto manages a diabetic Labrador using a Bluetooth-enabled glucose meter that syncs data to a mobile app. The veterinarian monitors the readings remotely and adjusts the insulin dosage when required — minimizing clinic visits, reducing costs, and lowering stress for both owner and pet.

 

This example reflects the market’s core direction: devices that combine simplicity, digital connectivity, and veterinary support drive the highest adoption and compliance rates. Companies that invest in user education, technical assistance, and mobile-friendly solutions will capture long-term customer loyalty.

 

Ultimately, the future of pet diabetes care lies in empowering owners with easy, accurate, and connected tools — supported by veterinary expertise whenever needed.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• In 2023, Zoetis launched a pilot for a wearable glucose sensor for dogs and cats in select U.S. clinics — full rollout expected by 2025.

• Boehringer Ingelheim Animal Health partnered with a human diabetes tech firm to adapt a leading CGM sensor for pets, with European regulatory filings underway.

• PetTest expanded its D2C lineup with a Bluetooth-enabled glucose meter integrated with a mobile app for home users.

 

Opportunities

• Remote Monitoring Expansion — App-synced CGMs open new revenue from data-based vet subscriptions.

• Insurance Bundles — Tying device costs to pet insurance plans can ease adoption barriers in developed markets.

• Emerging Markets — Rapid urban pet growth in China and Southeast Asia presents untapped potential for glucose meters and vet training services.

 

Restraints

• High Device Costs — CGMs and insulin pumps for pets remain expensive, limiting affordability.

• Skill Gap — Many owners lack experience in glucose monitoring and depend heavily on vet guidance.
   

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.8 Billion
Revenue Forecast in 2030	USD 2.8 Billion
Overall Growth Rate	CAGR of 7.5% (2024–2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024–2030)
Segmentation	By Product Type, By Animal Type, By End User, By Geography
By Product Type	Blood Glucose Monitoring Devices, Insulin Delivery Devices
By Animal Type	Dogs, Cats
By End User	Veterinary Hospitals & Clinics, Home Care
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, China, Japan, Australia, Brazil, India
Market Drivers	• Rising pet ownership & chronic disease awareness • Remote monitoring trends • Better veterinary infrastructure
Customization Option	Available upon request